Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Single Nucleotide Polymorphisms in MDS

A new scoring system for predicting survival

Publish date:: October 7, 2015

The single nucleotide polymorphisms (SNPs) TP53 R72P and MDM2 SNP309 SNPs in myelodysplastic syndromes (MDS) provide a novel scoring system independent of IPSS that is predictive for disease outcome. This according to an analysis of the interaction of TP53 R72P and MDM SNP309 in DNA isolated from 208 patients with MDS. Researchers found:

• Scored using a novel functional SNP system ranging from +2 to -2 based on predicted p53 activity, non –del(5q) patients with low functional scores had statistically significant differences in overall survival (OS) and progression free survival (PFS).

• In univariate analysis, only the International Prognostic Scoring System (IPSS) and the functional SNP score predicted OS and PFS in non-del(5q) patients.

• In multivariate analysis, the functional SNP score was independent of IPSS for OS and PFS.

Citation: McGraw KL, Cluzeau T, Sallman DA, et al. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. [Published online ahead of print September 25, 2015]. Oncotarget. doi: 10.18632/oncotarget.5255.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Myelodysplastic Syndrome

Second transplant a good salvage option for children with ALL, AML, or MDS,

Genetic analysis highlights value of germline variants in MDS, AML,

Antibody targeting ‘do not eat me’ signals is active in AML, MDS,

Combo proves most effective in HMA-naive, higher-risk MDS,

More abnormal cells linked to poorer ASCT outcomes in MDS,